. It is caused by maternal deficiency of the imprinted gene UBE3A, encoding an E3 ubiquitin ligase [3] [4] [5] . All patients carry at least one copy of paternal UBE3A, which is intact but silenced by a nuclear-localized long non-coding RNA, UBE3A antisense transcript (UBE3A-ATS) [6] [7] [8] . Murine Ube3a-ATS reduction by either transcription termination or topoisomerase I inhibition has been shown to increase paternal Ube3a expression 9, 10 . Despite a clear understanding of the disease-causing event in Angelman syndrome and the potential to harness the intact paternal allele to correct the disease, no gene-specific treatment exists for patients. Here we developed a potential therapeutic intervention for Angelman syndrome by reducing Ube3a-ATS with antisense oligonucleotides (ASOs). ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. Although additional studies of phenotypic correction are needed, we have developed a sequence-specific and clinically feasible method to activate expression of the paternal Ube3a allele.
Phosphorothioate-modified chimaeric 29-O-methoxyethyl (29-MOE) DNA ASOs (n 5 240) were designed complementary to a 113 kilobase pair (kb) region of mouse Ube3a-ATS downstream of the Snord115 cluster of small nucleolar RNAs (snoRNAs) (Fig. 1a) . After nuclear hybridization of the ASO to the target RNA, RNase H cleaves the RNA strand of the ASO-RNA heteroduplex, resulting in subsequent RNA degradation by exonucleases 11 . A high-throughput imaging screen identified ASOs that unsilenced the Ube3a paternal allele. Primary neurons from Ube3a 1/YFP (Pat YFP ) knock-in mice 12 were cultured and treated with ASO (15 mM, 72 h), and we determined the fold increase of paternal yellow fluorescent protein (YFP)-tagged UBE3A (UBE3A-YFP) signal in NeuN (also known as Rbfox3)-positive cells (Fig. 1b) . The non-targeting control ASO (Ctl ASO) had no effect on fluorescence (0.96 6 0.01) whereas the positive control topoisomerase I inhibitor (topotecan, 300 nM) increased fluorescence (3.61 6 0.00). ASO A and ASO B resulted in an increase in paternal UBE3A-YFP fluorescence of 2.11 6 0.02 and 2.47 6 0.03, respectively (Fig. 1c) . ASOs modulated RNA expression in a dosedependent manner with greater than 90% reduction of Ube3a YFP -ATS (Fig. 1d , top) within 48 h of treatment (Fig. 1d, bottom) .
Snrpn, Snord116 and Snord115 are processed from the same precursor transcript as Ube3a-ATS (Fig. 1a) and are critical genes in PraderWilli Syndrome (PWS) 13 . Their expression was not affected by increasing the dose or time of ASO treatment (Fig. 1d, e) . The ability to downregulate Ube3a-ATS without affecting Snord116 expression can be attributed to a fast rate of Snord116 splicing (approximately 30 min) relative to the length of time required for transcription of the 332 kb region between Snord116 and the ASO-binding site (approximately 80 min) (Extended Data Fig. 1 ). While Ube3a-ATS ASOs did not affect expression of mature Snord116 or its precursor, ASOs designed directly to Snord116 strongly reduced Snord116 and the entire Ube3a-ATS precursor transcript (Extended Data Fig. 1 ).
ASO treatment (10 mM, 24 h) specifically reduced Ube3a-ATS (1,000 kb) without affecting expression of five other long genes (Nrxn3, 1,612 kb; Astn2, 1,024 kb; Pcdh15, 828 kb; Csmd1, 1,643 kb; Il1rapl1, 1,368 kb), whereas topotecan (300 nM, 24 h), which acts by impairing transcription elongation 14 , strongly inhibited their expression (Fig. 1f) . Primary neurons from Pat YFP mice treated with ASO (10 mM, 72 h) or topotecan (300 nM, 72 h) resulted in biallelic UBE3A protein expression due to unsilencing of the paternal allele (Fig. 1g) . Additionally, ASO treatment of primary neurons from Ube3a KO/1 (Angelman syndrome) mice 15 achieved 66-90% of wild-type levels of UBE3A protein (Fig. 1h ). ASO treatment (10 mM) did not affect DNA methylation at the PWS imprinting centre (Fig. 1i) . A sequence-matched ASO that was rendered unresponsive to RNase H by complete modification with 29-MOE nucleotides (ASO, inactive) did not affect paternal UBE3A expression, indicating that reduction of the antisense transcript is required for paternal Ube3a unsilencing (Fig. 1g) .
Although reduction of the antisense transcript was required, additional studies indicated that it was not sufficient for paternal Ube3a unsilencing. ASOs complementary to the region of Ube3a YFP -ATS upstream of Ube3a (non-overlapping ASOs, n 5 15) upregulated Ube3a YFP RNA 7.4 6 0.6 fold relative to untreated control neurons (Extended Data Fig. 2) . ASOs complementary to the region of Ube3a YFP -ATS located within the Ube3a gene body (overlapping ASOs, n 5 12) only upregulated Ube3a YFP RNA 1.7 6 0.2 fold. Because both non-overlapping and overlapping ASOs reduced Ube3a YFP -ATS to a similar level, a mechanism independent of the presence of the long non-coding RNA may have a role in Ube3a silencing.
Next, we tested whether central nervous system (CNS) administration of Ube3a-ATS ASOs unsilenced paternal Ube3a in vivo. A single intracerebroventricular (ICV) injection of ASO was administered into the lateral ventricle of adult Pat YFP mice. The ASO treatment was generally well tolerated, despite transient sedation after surgery. No significant changes in body weight, expression of AIF1 (marker for microgliosis), or expression of GFAP (marker for astrocytosis) were observed 1 month after treatment (Extended Data Fig. 3 ). Four weeks after treatment, ASO A and ASO B reduced Ube3a-ATS RNA by 60-70% and upregulated paternal Ube3a
YFP RNA two-to five-fold in the brain and spinal cord (Fig. 2a) (Fig. 2a) . Western blot quantification showed that UBE3A-YFP protein was upregulated in the cortex (82 6 7%), hippocampus (33 6 3%) and thoracic spinal cord (73 6 33%) in ASO-A-treated Pat YFP mice compared with Mat YFP mice (Fig. 2b) . No significant downregulation of Snrpn, Snord116, Snord115, or the sentinel long genes was observed, including any Snord116 reduction in the hypothalamus (Fig. 2a, c and Extended Data Fig. 4) .
After a single ASO dose, Ube3a-ATS reduction was sustained for 16 weeks in the CNS, and returned to basal expression by 20 weeks after treatment (Fig. 2d) . Both the RNA and protein levels of paternal UBE3A-YFP were significantly higher than in PBS-treated mice at 2 to 16 weeks after treatment, and returned to the silenced state 20 weeks after treatment (Fig. 2d, e) . No significant changes in Snrpn, Snord115 or Snord116 expression were observed (Fig. 2d) . Immunostaining on brain sections 16 weeks after treatment further confirmed the long stability of the ASO and duration of paternal UBE3A protein expression (Extended Data   Fig. 5 ). This result is consistent with the long stability of other centrally administered ASOs that are chemically modified to resist intracellular nuclease degradation 16, 17 . After ICV delivery, the ASO displayed widespread bilateral distribution throughout the brain, as demonstrated by immunostaining (Fig. 3a) , and in situ hybridization confirmed the in vivo downregulation of Ube3a-ATS (Fig. 3b) . UBE3A-YFP protein was expressed in ASO-positive cells (Fig. 3c) . Increased UBE3A-YFP signal was detected in NeuN-positive cells throughout the brain (Fig. 3d and Extended Data Figs 6 and 7). 
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However, paternal unsilencing was not complete compared with the maternal UBE3A-YFP level, consistent with the western blot analysis. To further increase the concentration of ASO in the brain, intrahippocampal delivery of ASO A was performed in Pat YFP mice and complete unsilencing of UBE3A-YFP was observed near the injection site (Extended Data Fig. 8) .
On the basis of the ability of ASO A to upregulate UBE3A, it was chosen for assessment of phenotypic correction in Angelman syndrome mice. Angelman syndrome mice phenocopy the impaired motor coordination and memory deficit observed in patients with the disease 15 . They have additional phenotypes including obesity, hypoactivity and decreased marble burying behaviour [18] [19] [20] . Sex-matched Angelman syndrome littermates at 2-4 months of age were treated with ASO A or non-targeting control ASO (Ctl ASO). To determine the ability of ASO A to correct expression and behaviours relative to wild-type levels, a group of PBStreated wild-type mice was included. After a single ICV injection, Angelman syndrome mice treated with ASO A showed reduction of Ube3a-ATS and partial restoration of UBE3A protein in the cortex (35 6 19%), hippocampus (35 6 15%) and cerebellum (47 6 7%) compared with wildtype mice (Fig. 4b and Extended Data Fig. 9 ). UBE3A immunofluorescence also showed partial restoration of UBE3A protein in these brain regions ( Fig. 4c and Extended Data Fig. 9 ). Four weeks after treatment, the mice were subjected to behavioural tests. A reversal of contextual freezing comparable to normal behaviour was observed in ASO-A-treated Angelman syndrome mice (analysis of variance (ANOVA), F(2,39) 5 5.242, P , 0.01), indicating that the memory impairment was reversed ( Fig. 4d and Extended Data Fig. 9 ). However, there was no difference between mice treated with ASO A or Ctl ASO in open field, marble burying and accelerating rotarod tests (Extended Data Fig. 9 ). Complete phenotypic reversal may require treatment before a critical developmental window, a longer recovery time for rewiring of neural circuits, or a higher UBE3A induction level. Body weight was measured in a set of female mice that were injected at 3 months of age and followed for 5 months (Fig. 4e and Extended Data Fig. 9 ). The obesity phenotype in Angelman syndrome mice was corrected 1 month after treatment, and body weight remained significantly decreased compared with control ASO-treated mice for 5 months.
The genomic organization and regulation at the imprinting control centre is highly conserved between mouse and human. Therefore, ASOmediated reduction of UBE3A-ATS is expected to restore UBE3A messenger RNA and protein in Angelman syndrome patient neurons. It is believed that maternal deficiency of UBE3A causes the majority of phenotypic findings in Angelman syndrome, and it is reasonable to expect that all patients with the condition, regardless of exact genotype, would benefit enormously from restored UBE3A expression. ASO therapy has been tested for neurological diseases in non-human primates and human clinical trials via intrathecal administration, with no serious adverse events 16, [21] [22] [23] . The well-tolerated delivery, broad tissue distribution and long duration of action indicate that ASOs may be a viable therapeutic strategy for CNS diseases and highlights the potential of an ASO drug for Angelman syndrome. 
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Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 4 KO/1 mice were born to mothers who carry the mutation on their paternal chromosome. Wildtype and Angelman syndrome littermates were housed in the same cage whenever possible. Oligonucleotide synthesis. Synthesis and purification of all chemically modified oligonucleotides was performed as previously described Primary neuron culture and ASO treatment. Primary cultures of hippocampal and cortical neurons were established as previously described 8 from P0-P2 offspring of wild-type C57BL/6 or Ube3a 1/YFP mice. Four days after plating, half of the medium was replaced and the ASO (10 mM) or topotecan (300 nM) was added to the culture medium for 72 h, unless otherwise noted. Arabinofuranosyl cytidine (Sigma) was used to inhibit glial proliferation. Immunofluorescence. Primary neurons were fixed with 4% paraformaldehyde (PFA) for 1 h and washed in PBS. For in vivo samples, mice were anaesthetized and perfused with PBS and 4% PFA. Brain tissue was fixed with PFA overnight and dehydrated in 30% sucrose. Coronal sections of 35 mm were prepared and stained as previously described 9 . The following antibodies were used: anti-GFP (ab13970, Abcam, 1:1,000), anti-NeuN (MAB377, Millipore, 1:1,000 dilution), anti-UBE3A (A300-352A, Bethyl Laboratories,1:500), and anti-ASO (Isis, 1:10,000) 26 . For the highthroughput in vitro ASO screen, the plates were imaged with ImageXpress Ultra confocal system (Molecular Device) and then further processed with the MetaXpress software (Molecular Device). Typically 200-800 cells were scored per well and the signal intensities were averaged and normalized to untreated control cells. For tissue sections, images were taken using a confocal microscope (Leica). qRT-PCR. Total cellular RNA was isolated from cultured neurons and mouse tissue using the RNeasy kit (Qiagen). For preparation of mouse tissue, samples were first lysed using FastPrep Lysing Matrix Tubes (MP-Biomedicals) in RLT buffer containing 1% b-mercaptoethanol. On-column DNase digestion was performed for all samples. For qRT-PCR, approximately 10 ng RNA was added to EXPRESS One-Step SuperScript qRT-PCR Kit (Life Technologies) with Taqman primer and probe sets or EXPRESS One-Step SYBR GreenER Kit (Life Technologies) with SYBR primer sets (see Extended Data Table 1 for sequences). All quantification was performed by the relative standard curve method and normalized to total RNA by Ribogreen or to the housekeeping genes Gapdh. DNA methylation analysis. Primary neuron cultures were derived from the F1 hybrid of CAST.chr7 male and C57BL/6 female mice and treated with ASO (10 mM, 72 h). Genomic DNA was then extracted and processed for bisulphite sequencing of the PWS imprinting centre at the Snrpn DMR1 region (Snrpn promoter and exon 1) as previously described 8 . Northern blot. Total RNA was isolated from ASO-treated primary neurons (10 mM, 72 h) by TRIzol (Life Technologies) according to the manufacturer's protocol. Three micrograms total RNA was separated on an 8% polyacrylamide-7M urea gel, and then transferred by semi-dry transfer (12 V, 30 min) to GeneScreen plus hybridization transfer membrane (Perkin Elmer). The northern probes were 59-end labelled with ATP Gamma 32 P (Perkin Elmer) using T4 polynucleotide kinase (New England Biolabs), and then hybridized to the membrane at 42 uC for 30 min. After washing membrane in wash buffer (23 SSC containing 0.1% SDS), the membrane was exposed to a PhosphorImager and quantified. The oligonucleotide probe sequences used were Snord116 59-TTCCGATGAGAGTGGCGGTACAGA-39 and 5.8S rRNA 59-TCCTGCAATTCACATTAATTCTCGCAGCTAGC-39. Western blot. Cultured neurons and mouse tissue were homogenized and lysed in RIPA buffer (Sigma-Aldrich) containing EDTA-free cOmplete Protease Inhibitor Cocktail (Roche). Protein concentration of the supernatant was determined by the DC protein assay (Bio-Rad). Ten to forty micrograms of protein lysate was separated on a precast 4-20% Bis-Tris gel (Life Technologies) and transferred by iBlot (Life Technologies). The following primary antibodies were diluted in Odyssey blocking buffer: anti-UBE3A (611416, BD Biosciences, 1:500), anti-GFP (NB600-308, Novus Biologicals, 1:500), anti-b-tubulin (T9026, Sigma, 1:20,000) and anti-a-tubulin (T5168, Sigma, 1:8,000). Following primary antibody incubation, membranes were probed with goat anti-rabbit IRDye 680LT (LiCor) or goat anti-mouse IRDye 800CW (LiCor) and imaged and quantified using the LiCor Odyssey system. ASO in vivo administration. Lyophilized ASOs were dissolved in sterile PBS without calcium or magnesium and quantified by ultraviolet spectrometry. The ASOs were then diluted to the desired concentration required for dosing mice and sterilized through a 0.2 mm filter. Mice were anaesthetized with 2% isoflurane and placed in a stereotaxic frame (David Kopf Instruments). After exposing the skull, a needle (Hamilton, 1701 RN 10 ml micro syringe, needle 26 s/299/2) was used to penetrate the skull at 0.2 mm posterior and 1.0 mm lateral to the bregma, and lowered to a depth of 3.0 mm, to deliver PBS or ASO (ASO A, 700 mg; ASO B, 500 mg) at a rate of approximately 1 ml per 30 s. The needle was left in place for 5 min, slowly withdrawn and the incision was sutured. For intrahippocampal injection, the coordinate of 22.0 mm anterior, 1.5 mm lateral and 22.0 mm dorsal to the bregma was used. Fluorescence in situ hybridization. Tissue preparation and RNA fluorescence in situ hybridization (FISH) was carried out by the RNA In-Situ Hybridization Core at Baylor College of Medicine, as previously described 9 . Primers for DNA template synthesis are 59-ATTTAGGTGACACTATAGAAGCGAAGATGAGTCAGTTT GGTTTT-39 and 59-TAATACGACTCACTATAGGGAGATTCTGAGTCTTCT TCCATAGC-39. The T7 promoter was used to generate the Ube3a-ATS probe. Behavioural tests. Three groups of age-and sex-matched littermates were generated, and mice were randomly assigned to each treatment group. At 2 to 4 months of age, Angelman syndrome mice received a single 700 mg dose of non-targeting control ASO or ASO A. Wild-type mice injected with an equal volume of PBS were included as controls. Four weeks after treatment, a battery of behavioural tests was performed by an experimenter blind to the genotype and treatment group using a protocol previously described 9 in the Neurobehavioural Core at Baylor College of Medicine. The open field and marble burying tests were performed on day 1, the accelerating rotarod test was performed on day 2 and 3, and the fear conditioning test was performed on day 4 and 5. Mice were acclimated to the test room for 30 min before each behaviour test.
For the open field assay each mouse was placed in the centre of a clear Plexiglas (40 3 40 3 30 cm) open-field arena (Versamax Animal Activity Monitor, AccuScan Instruments) and allowed 30 min to explore. Overhead lighting was ,800 lx inside the field, and the white noise was at ,60 dB. Mouse activity was recorded and quantified.
For the marble burying test, each mouse was placed in a standard mouse cage containing 20 small (1.5-2 cm) clean black marbles on top of 4 inches of corn cob bedding, forming 4 rows of 5 columns. After a period of 30 min exploration, the mouse was removed from the cage and the number of marbles buried at least 50% was recorded.
For the accelerating rotarod, the test was performed with a rotating rod system that rotates from 4 to 40 r.p.m. within 5 min (model 7650 Rota-rod, Ugo Basile). Mice were placed on the rotating rod and the time until falling off or losing balance (mice not walking on the rod for two consecutive turns) was recorded. For two consecutive days, four trials were performed per day with at least a 30 min interval between trials.
For contextual fear conditioning, on the training day, each mouse was placed in a test chamber. After 2 min of free exploration (baseline/pre-shock freezing), the mouse received an auditory tone (2,800 Hz, 85 db, 30 s) followed by a foot-shock (0.7 mA, 2 s). The training was repeated once. The mouse remained in the chamber for one additional min (post-shock freezing) and then was returned to the home cage. Twenty-four hours after training, mice were returned to the same test chamber for 5 min and tested for freezing in response to the training context (contextual freezing). Afterwards, the environmental settings of the test chamber were drastically altered and the mice were placed back in the modified context. They were allowed 3 min of free exploration, and then the auditory tone was presented for 3 min to test the fear response to the cue (cued freezing). Freezing frequency was analysed with FreezeFrame software (San Diego Instruments). Isolation of nascent RNA. Nascent RNA was isolated using the Click-iT Nascent RNA Capture Kit (Life Technologies), according to the manufacturer's protocol. In brief, wild-type primary neurons were incubated with 5-ethynyl uridine (EU, 0.5 mM) for 0 to 150 min at which time total RNA was isolated by TRIzol. Five micrograms total RNA was biotinylated with 0.5 mM biotin azide, and 500 ng biotinylated RNA was precipitated on streptavidin beads. Nascent EU-containing RNA captured on the beads was used for SuperScript VILO cDNA synthesis (Life Technologies) followed by qPCR. 
